Lana C, a cardiac glycoside used for the treatment of cardiovascular diseases, is known to inhibit the transmembrane protein sodium-potassium adenosine triphosphatase (Na<sup>+</sup>/K<sup>+</sup>-ATPase). This evidence concerns the gene DNAH8 and cardiovascular disorder.